IN THE CLAIMS

Applicant has attached Appendix D wherein the amended claims are presented in clean form. Applicant has attached Appendix E, wherein the amended claims are presented in marked-up form.

REMARKS

Claims 1-23 and 42-56 are currently pending in this application.

Applicants have amended the specification to correct various informalities as discussed in more detail below.

Applicants have amended claims 1 and 3 to recite that the cell culture comprises at least 90% GFAP⁺ cells. Support for this amendment can be found in the specification, for example, on page 6, line 6, page 8, line 12, page 28, line 19, or page 22, lines 21-23.

Applicants have amended claim 5 to depend solely from claim 1.

Applicants have amended claim 9 to correct a typographical error.

Applicants have amended claims 2, 4, 7, 44, 44, 46, 48, 50, 51, 53, and 55 to delete the term "majority" and substitute the phrase "greater than 50%".

Applicants have amended claims 18 and 20 to delete the term "some" and substitute the phrase "a portion".

None of the amendments presented herein constitute new matter. Applicants reserve the right to pursue canceled subject matter in applications claiming priority to the instant application. Applicants address below the outstanding objections and rejections.

THE INFORMATION DISCLOSURE STATEMENT

The Examiner has objected to the previously filed Information Disclosure Statement contending that it failed to comply with 37 C.F.R. 1.98(a)(2). Applicants will contact the Examiner to determine the exact deficiency and will prepare the documents for filing.

THE OATH/DECLARATION

The Examiner objected to the oath/declaration contending that non-initialed changes